Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-Cells
Authors:
Open Access
- 10 February 2021
- journal article
- case report
- Published by Wiley in HemaSphere
- Vol. 5 (3) , e533
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Glial injury in neurotoxicity after pediatric CD19‐directed chimeric antigen receptor T cell therapyAnnals of Neurology, 2019
- Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cellsBlood, 2019
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Double-negative T cells remarkably promote neuroinflammation after ischemic strokeProceedings of the National Academy of Sciences, 2019
- CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future DirectionsJNCI: Journal of the National Cancer Institute, 2019
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cellsNature Medicine, 2018
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- Chimeric Antigen Receptor T Cells in Refractory B-Cell LymphomasNew England Journal of Medicine, 2017
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T CellsCancer Discovery, 2017